Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens V, Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108–18.

Article  PubMed  Google Scholar 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Cao G, Liu J, Liu M. Global, regional, and national trends in incidence and mortality of primary liver cancer and its underlying etiologies from 1990 to 2019: results from the global burden of disease study 2019. J Epidemiol Glob Health. 2023;13(2):344–60.

Article  PubMed  PubMed Central  Google Scholar 

Rastin F, Javid H, Oryani MA, Rezagholinejad N, Afshari AR, Karimi-Shahri M. Immunotherapy for colorectal cancer: rational strategies and novel therapeutic progress. Int Immunopharmacol. 2024;126: 111055.

Article  CAS  PubMed  Google Scholar 

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52.

Article  PubMed  Google Scholar 

Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11): e204564.

Article  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905.

Article  CAS  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72.

Article  CAS  PubMed  Google Scholar 

Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De Toni EN, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):2100070.

Article  Google Scholar 

Javid H, Attarian F, Saadatmand T, Rezagholinejad N, Mehri A, Amiri H, Karimi-Shahri M. The therapeutic potential of immunotherapy in the treatment of breast cancer: rational strategies and recent progress. J Cell Biochem. 2023;124(4):477–94.

Article  CAS  PubMed  Google Scholar 

Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53.

Article  PubMed  Google Scholar 

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.

Article  CAS  PubMed  Google Scholar 

Shin J, Kang N, Kim B, Hong H, Yu L, Kim J, Kang H, Kim JS. One-dimensional nanomaterials for cancer therapy and diagnosis. Chem Soc Rev. 2023;52(13):4488–514.

Article  CAS  PubMed  Google Scholar 

Ramesh S, Govarthanan K, Palaniappan A. TiO(2) nanostructures - a double edged sword: current progress on their role in stem cells’ differentiation, cancer therapy, and their toxicity issues. Nanotoxicology. 2023;17(2):176–201.

Article  CAS  PubMed  Google Scholar 

Javid H, Oryani MA, Rezagholinejad N, Hashemzadeh A, Karimi-Shahri M. Unlocking the potential of RGD-conjugated gold nanoparticles: a new frontier in targeted cancer therapy, imaging, and metastasis inhibition. J Mater Chem B. 2024. https://doi.org/10.1039/D4TB00281D.

Article  PubMed  Google Scholar 

Rastin F, Oryani MA, Iranpour S, Javid H, Hashemzadeh A, Karimi-Shahri M. A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery. J Mater Chem B. 2024;12(4):872–94.

Article  CAS  PubMed  Google Scholar 

Oryani MA, Nosrati S, Javid H, Mehri A, Hashemzadeh A, Karimi-Shahri M. Targeted cancer treatment using folate-conjugated sponge-like ZIF-8 nanoparticles: a review. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(3):1377–404.

Article  CAS  PubMed  Google Scholar 

Yin X, Rong J, Shao M, Zhang S, Yin L, He Z, Wang X. Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma. J Nanobiotechnol. 2024;22(1):243.

Article  Google Scholar 

Ma HL, Xu YF, Qi XR, Maitani Y, Nagai T. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm. 2008;354(1–2):217–26.

Article  CAS  PubMed  Google Scholar 

Chiang CF, Hsu YH, Hsieh WY, Liao TH, Chen CL, Chen YC, Liang PC, Wang SJ. IOP injection, a novel superparamagnetic iron oxide particle MRI contrast agent for the detection of hepatocellular carcinoma: a phase II clinical trial. J Magn Reson Imaging. 2023;58(4):1177–88.

Article  PubMed  Google Scholar 

Yin T, Wang P, Li J, Wang Y, Zheng B, Zheng R, Cheng D, Shuai X. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials. 2014;35(22):5932–43.

Article  CAS  PubMed  Google Scholar 

Wu B, Shang H, Liang X, Sun Y, Jing H, Han X, Cheng W. Preparation of novel targeting nanobubbles conjugated with small interfering RNA for concurrent molecular imaging and gene therapy in vivo. Faseb J. 2019;33(12):14129–36.

Article  CAS  PubMed  Google Scholar 

Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11(11):5464–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Babos G, Biró E, Meiczinger M, Feczkó T. Dual drug delivery of sorafenib and doxorubicin from PLGA and PEG-PLGA polymeric nanoparticles. Polymers (Basel). 2018. https://doi.org/10.3390/polym10080895.

Article  PubMed  Google Scholar 

Yao Y, Wang T, Liu Y, Zhang N. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):1374–83.

Article  CAS  PubMed  Google Scholar 

Iacobazzi RM, Vischio F, Arduino I, Canepa F, Laquintana V, Notarnicola M, Scavo MP, Bianco G, Fanizza E, Lopedota AA, et al. Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. J Colloid Interface Sci. 2022;608(Pt 1):239–54.

Article  CAS  PubMed  Google Scholar 

Zhou F, Teng F, Deng P, Meng N, Song Z, Feng R. Recent progress of nano-drug delivery system for liver cancer treatment. Anticancer Agents Med Chem. 2018;17(14):1884–97.

Article  PubMed  Google Scholar 

Alhalmi A, Beg S, Kohli K, Waris M, Singh T. Nanotechnology based approach for hepatocellular carcinoma targeting. Curr Drug Targets. 2021;22(7):779–92.

CAS  PubMed  Google Scholar 

Ma L, Ma J, Teng M, Li Y. Visual analysis of colorectal cancer immunotherapy: a bibliometric analysis from 2012 to 2021. Front Immunol. 2022;13: 843106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hwang JW, Kim H, Lee DJ. The 100 most influential manuscripts on hepatocellular carcinoma: a bibliometric analysis. J Int Med Res. 2019;47(4):1467–82.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Zheng H, Jiang ST, Liu YG, Zhang T, Zhang JW, Lu X, Zhao HT, Sang XT, Xu YY. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis. Int J Surg. 2024;110(3):1699–710.

Article  PubMed